Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 160 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 5-ala Clear all
Recruiting Phase 2 Interventional

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

NCT04370301
View directory record Official record
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Computed Tomography, Magnetic Resonance Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 23, 2026, 6:12 PM EDT
Terminated Phase 1 Interventional Results available

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

NCT02483000
View directory record Official record
Conditions
Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, Diffuse Large B-Cell Lymphoma, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Clearing Agent, Cytarabine, Etoposide, Indium In 111-DOTA-Biotin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Yttrium Y 90-DOTA-Biotin
Biological · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

NCT01904136
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Therapy-Related Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide, Fludarabine, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Natural Killer Cell Therapy, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

NCT05662202
View directory record Official record
Conditions
Actinic Keratoses
Interventions
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Greenwood Village, Colorado • Delray Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 6:12 PM EDT
Active, not recruiting Phase 3 Interventional

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

NCT05457556
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Busulfan, Cyclophosphamide, Echocardiography Test, Fludarabine, Haploidentical Hematopoietic Cell Transplantation, Lapine T-Lymphocyte Immune Globulin, Lumbar Puncture, Matched Unrelated Donor Hematopoietic Cell Transplantation, Melphalan, Methotrexate, Multigated Acquisition Scan, Mycophenolate Mofetil, Myeloablative Conditioning, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, T-Cell Depletion Therapy, Tacrolimus, Thiotepa, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 3 Interventional

Fluorescence-guided Surgery for Low- and High-grade Gliomas

NCT01502280
View directory record Official record
Conditions
Glioma
Interventions
5-Aminolevulinic acid (ALA), Placebo - ascorbic acid
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 23, 2026, 6:12 PM EDT
Terminated Not applicable Interventional Results available

Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis

NCT00524485
View directory record Official record
Conditions
Precancerous/Nonmalignant Condition
Interventions
aminolevulinic acid, laser therapy
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 23, 2026, 6:12 PM EDT
Active, not recruiting Phase 1 Interventional

ALA-induced PpIX Fluorescence During Brain Tumor Resection

NCT02191488
View directory record Official record
Conditions
Brain Tumors
Interventions
5-aminolevulinic acid
Drug
Lead sponsor
David W. Roberts
Other
Eligibility
21 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

NCT03426969
View directory record Official record
Conditions
Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Melphalan, Mycophenolate Mofetil, Tacrolimus, Total-Body Irradiation
Drug · Biological · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Not applicable Interventional Results available

Near Infrared Fluorescence Imaging for Bladder Cancer Detection

NCT03058705
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexaminolevulinate HCL, Near Infrared Fluorescence (NIRF)
Drug · Device
Lead sponsor
Edward Messing
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01256398
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions
Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide Phosphate, Filgrastim, Fludarabine Phosphate, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Leucovorin Calcium, Melphalan, Mercaptopurine, Methotrexate, Pegfilgrastim, Pharmacological Study, Tacrolimus, Vincristine Sulfate
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
101
States / cities
Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

NCT00005803
View directory record Official record
Conditions
Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cyclosporine, Cytarabine, Etoposide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Therapeutic Autologous Lymphocytes, Total-Body Irradiation
Procedure · Drug · Other + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 23, 2026, 6:12 PM EDT
Recruiting Phase 2 Interventional

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

NCT07582172
View directory record Official record
Conditions
Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Refractory Secondary Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Fludarabine Phosphate, Melphalan, Multigated Acquisition Scan, Palifermin, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

NCT04339101
View directory record Official record
Conditions
Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Fludarabine, Itacitinib Adipate, Melphalan, Quality-of-Life Assessment, Questionnaire Administration, Sirolimus, Tacrolimus
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 23, 2026, 6:12 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Metabolic Effects of Steroids in Obese Men

NCT00983554
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Anastrazole, Testosterone, Dutasteride, GnRH antagonist
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
24 Years to 51 Years · Male only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

NCT05362409
View directory record Official record
Conditions
High Grade Glioma
Interventions
5 Aminolevulinic Acid, CV01-delivered ultrasound
Drug · Device
Lead sponsor
Alpheus Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
St Louis, Missouri • Amherst, New York • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 23, 2026, 6:12 PM EDT
Active, not recruiting Phase 1 Interventional

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis

NCT03118492
View directory record Official record
Conditions
Secondary Myelofibrosis
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine, Glycosylated Recombinant Human G-CSF AVI-014, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency

NCT02991144
View directory record Official record
Conditions
Ornithine Transcarbamylase (OTC) Deficiency
Interventions
scAAV8OTC, Reactive Corticosteroid Taper Regimen, Prophylactic Corticosteroid Taper Regimen
Genetic · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 3 Interventional Results available

A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting

NCT02560584
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexaminolevulinate hydrochloride, KARL STORZ D-Light C PDD Flexible Videoscope System
Drug · Device
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Los Angeles, California • Chicago, Illinois • Iowa City, Iowa + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 23, 2026, 6:12 PM EDT
Suspended Phase 1 Interventional

Phase I Study in Advanced Malignancies With 5-ALA

NCT04381806
View directory record Official record
Conditions
Solid Tumor
Interventions
5-ALA
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors

NCT01128218
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Tumor fluorescence
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 23, 2026, 6:12 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Photodynamic Therapy for Cutibacterium Acnes (C. Acnes) Decolonization of the Shoulder Dermis

NCT04636242
View directory record Official record
Conditions
C. Acnes, Phototherapy, Postoperative Infection, Arthroscopic Rotator Cuff Repair, Shoulder Surgery
Interventions
Skin Biopsy, 5 Aminolevulinic Acid + Phototherapy
Procedure · Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 23, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

NCT02756572
View directory record Official record
Conditions
Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-2, Myeloid Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cladribine, Cyclosporine, Cytarabine, Filgrastim, Fludarabine Phosphate, Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Melphalan, Mitoxantrone Hydrochloride, Mycophenolate Mofetil, Questionnaire Administration, Sirolimus, Total-Body Irradiation, Melphalan Hydrochloride
Drug · Biological · Procedure + 2 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 23, 2026, 6:12 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer

NCT01522677
View directory record Official record
Conditions
Colon Cancer
Interventions
PDT with 5-ALA radiosensitization
Drug
Lead sponsor
Edward Nelson
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Orange, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 23, 2026, 6:12 PM EDT